Oncogene:MicroRNA-1205与去势难治性前列腺癌风险有关

2019-03-14 AlexYang MedSci原创

染色体8q24.21位点包含了原癌基因c-MYC、长非编码RNA PVT1和microRNAs(miRs),是人类前列腺癌中最常见的扩增区域。遗传变异与该位点的c-MYC和长非编码RNA PVT1长期互作能够导致前列腺癌的遗传风险。在该位点包含6个miRs(miR-1204, -1205, -1206, -1207-3p, -1207-5p和-1208),但是他们的功能仍旧未知。最近,有研究人员利

染色体8q24.21位点包含了原癌基因c-MYC、长非编码RNA PVT1和microRNAs(miRs),是人类前列腺癌中最常见的扩增区域。遗传变异与该位点的c-MYC和长非编码RNA PVT1长期互作能够导致前列腺癌的遗传风险。在该位点包含6个miRs(miR-1204, -1205, -1206, -1207-3p, -1207-5p和-1208),但是它们的功能仍旧未知。

最近,有研究人员利用实时定量PCR对前列腺癌细胞系和原发性肿瘤中的miRs-1204-1208的拷贝数和表达水平进行了调查。数据表明miR-1205的拷贝数和表达水平在去势难治性前列腺癌细胞系和原发性肿瘤中均增加。在势难治性前列腺癌样本中,miR-1205位点的拷贝数与miR-1205的表达有关。更多的是,miR-1205的一个抑制子分析和CRISPR/Cas9敲除试验阐释了在人类前列腺细胞中,miR-1205能够促进细胞增殖和细胞周期进展以及抑制过氧化氢诱导的细胞凋亡。在这些细胞中,miR-1205能够下调Egl-9家族缺氧诱导因子3(EGLN3)的表达,并靶向其3'非翻译区来下调其转录活性。

最后,研究人员指出,通过靶向EGLN3,miR-1205具有致瘤的作用,并且可能导致前列腺癌的遗传风险。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2022578, encodeId=227b20225e816, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Thu Jul 11 12:45:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061834, encodeId=1c552061834df, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Aug 30 16:45:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049162, encodeId=193e20491625a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Feb 12 09:45:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857768, encodeId=3310185e768a4, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Feb 09 09:45:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084498, encodeId=12f72084498ec, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Nov 15 17:45:00 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435753, encodeId=02231435e53bc, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528554, encodeId=f685152855451, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558148, encodeId=7b1f1558148ee, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2022578, encodeId=227b20225e816, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Thu Jul 11 12:45:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061834, encodeId=1c552061834df, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Aug 30 16:45:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049162, encodeId=193e20491625a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Feb 12 09:45:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857768, encodeId=3310185e768a4, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Feb 09 09:45:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084498, encodeId=12f72084498ec, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Nov 15 17:45:00 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435753, encodeId=02231435e53bc, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528554, encodeId=f685152855451, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558148, encodeId=7b1f1558148ee, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=)]
    2019-08-30 sjq027
  3. [GetPortalCommentsPageByObjectIdResponse(id=2022578, encodeId=227b20225e816, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Thu Jul 11 12:45:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061834, encodeId=1c552061834df, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Aug 30 16:45:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049162, encodeId=193e20491625a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Feb 12 09:45:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857768, encodeId=3310185e768a4, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Feb 09 09:45:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084498, encodeId=12f72084498ec, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Nov 15 17:45:00 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435753, encodeId=02231435e53bc, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528554, encodeId=f685152855451, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558148, encodeId=7b1f1558148ee, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=)]
    2020-02-12 cy0324
  4. [GetPortalCommentsPageByObjectIdResponse(id=2022578, encodeId=227b20225e816, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Thu Jul 11 12:45:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061834, encodeId=1c552061834df, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Aug 30 16:45:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049162, encodeId=193e20491625a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Feb 12 09:45:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857768, encodeId=3310185e768a4, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Feb 09 09:45:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084498, encodeId=12f72084498ec, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Nov 15 17:45:00 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435753, encodeId=02231435e53bc, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528554, encodeId=f685152855451, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558148, encodeId=7b1f1558148ee, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2022578, encodeId=227b20225e816, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Thu Jul 11 12:45:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061834, encodeId=1c552061834df, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Aug 30 16:45:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049162, encodeId=193e20491625a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Feb 12 09:45:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857768, encodeId=3310185e768a4, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Feb 09 09:45:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084498, encodeId=12f72084498ec, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Nov 15 17:45:00 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435753, encodeId=02231435e53bc, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528554, encodeId=f685152855451, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558148, encodeId=7b1f1558148ee, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=)]
    2019-11-15 xjy02
  6. [GetPortalCommentsPageByObjectIdResponse(id=2022578, encodeId=227b20225e816, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Thu Jul 11 12:45:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061834, encodeId=1c552061834df, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Aug 30 16:45:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049162, encodeId=193e20491625a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Feb 12 09:45:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857768, encodeId=3310185e768a4, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Feb 09 09:45:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084498, encodeId=12f72084498ec, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Nov 15 17:45:00 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435753, encodeId=02231435e53bc, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528554, encodeId=f685152855451, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558148, encodeId=7b1f1558148ee, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=)]
    2019-03-16 zhouqu_8
  7. [GetPortalCommentsPageByObjectIdResponse(id=2022578, encodeId=227b20225e816, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Thu Jul 11 12:45:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061834, encodeId=1c552061834df, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Aug 30 16:45:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049162, encodeId=193e20491625a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Feb 12 09:45:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857768, encodeId=3310185e768a4, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Feb 09 09:45:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084498, encodeId=12f72084498ec, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Nov 15 17:45:00 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435753, encodeId=02231435e53bc, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528554, encodeId=f685152855451, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558148, encodeId=7b1f1558148ee, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=)]
    2019-03-16 freve
  8. [GetPortalCommentsPageByObjectIdResponse(id=2022578, encodeId=227b20225e816, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Thu Jul 11 12:45:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061834, encodeId=1c552061834df, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Aug 30 16:45:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049162, encodeId=193e20491625a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Feb 12 09:45:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857768, encodeId=3310185e768a4, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Feb 09 09:45:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084498, encodeId=12f72084498ec, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Nov 15 17:45:00 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435753, encodeId=02231435e53bc, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528554, encodeId=f685152855451, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558148, encodeId=7b1f1558148ee, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Mar 16 04:45:00 CST 2019, time=2019-03-16, status=1, ipAttribution=)]
    2019-03-16 zsyan

相关资讯

Sci Rep:前列腺癌中白蛋白结合的肿瘤靶向前体药物研究

蛋白质转换酶PACE4已经确认为是开发前列腺癌干预的新治疗方法潜在的靶标。到目前为止,能够阻断该酶活性最有效的化合物是基于一个小分子肽Ac-LLLLRVKR-NH2(即Multi-Leu(ML)肽)来设计的。该化合物的优化能够导致化合物C23(Ac-[DLeu]LLLRVK-amidinobenzylamide)的合成,并在体内具有抑制肿瘤生长的潜力。然而,PACE4抑制子还需要进一步的开发,主要

Ann Intern Med:低剂量阿司匹林与前列腺癌诊断后死亡率的关系

由此可见,该研究不支持诊断后低剂量阿司匹林对前列腺癌死亡率的总体影响。然而,延长暴露的结果表明,使用低剂量阿司匹林可能与癌症诊断5年后的前列腺癌死亡率呈负相关。

Sci Rep:二甲双胍治疗对前列腺癌发生率和预后影响研究

二甲双胍与前列腺癌(PCa)之间的关系仍旧具有争议。最近,有研究人员为了鉴定两者之间的相互关系,他们系统的搜索了PubMed、Embase和Cochrane图书馆数据库,文献截止日期为2018年5月23日,所使用的关键词为二甲双胍和前列腺癌,从而来搜书相关研究。结果包括了发生率、总生存(OS)、PCa特异性生存(CSS)和无复发生存(RFS),并利用Review Manager5.3软件对风险比(

JCO:PROSTVAC在转移性去势抵抗性前列腺癌中的III期试验

PROSTVAC是一种基于病毒载体的免疫疗法,在II期研究中,与安慰剂相比,接受治疗的转移性去势抵抗性前列腺癌患者的中位总生存期(OS)延长了8.5个月。

Oncogenesis:二氢青蒿素能够通过JARID2/miR-7/miR-34a依赖的Axl下调来抑制前列腺癌

Axl的表达在一些癌症类型中不受调控,并且能够预测不良总患者生存,且与药物治疗抗性的产生有关。最近,有研究人员评估了Axl天然化合物抑制剂库,鉴定了二氢青蒿素(有效成分为抗疟疾药物青蒿素)可以作为前列腺癌中Axl的抑制剂。研究发现,二氢青蒿素能够阻断Axl的表达从而导致细胞凋亡,减少前列腺癌细胞的细胞增殖、迁移和肿瘤发生。多烯紫杉醇是转移性前列腺癌的标准治疗药物,能够增加人类异种种植小鼠模型的总生

Prostate Cancer P D:MEK-ERK信号是转移去势抵抗性前列腺癌的治疗靶标

转移去势抵抗性前列腺癌(mCRPC)目前难以治愈,以雄激素受体信号为靶标的药物治疗后的恶化也难以避免。因此,除了激素治疗手段外,开发更多有效的治疗方法非常迫切。最近,有研究人员鉴定了已经存在药物和改善过的药物对mCRPC中激活的激酶作为治疗靶标的可能性,目的在于鉴定候选药物从而实现快速将其进入mCRPC概念验证第二阶段试验。研究包括了101名患有mCRPC的患者。研究人员将这101名mCRPC患者